

Dirk Beher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1439749/publications.pdf>

Version: 2024-02-01

13
papers

727
citations

840585

11
h-index

1199470

12
g-index

13
all docs

13
docs citations

13
times ranked

902
citing authors

#	ARTICLE	IF	CITATIONS
1	Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target β -Secretase at a Novel Site. <i>Journal of Biological Chemistry</i> , 2004, 279, 43419-43426.	1.6	171
2	Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 9.	3.0	137
3	In Vitro Characterization of the Presenilin-Dependent β -Secretase Complex Using a Novel Affinity Ligand. <i>Biochemistry</i> , 2003, 42, 8133-8142.	1.2	79
4	Generation of C-terminally truncated amyloid- β peptides is dependent on β -secretase activity. <i>Journal of Neurochemistry</i> , 2002, 82, 563-575.	2.1	76
5	The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 1365-1370.	3.3	71
6	Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 1385-1409.	1.9	53
7	Functional Overexpression of β -Secretase Reveals Protease-independent Trafficking Functions and a Critical Role of Lipids for Protease Activity. <i>Journal of Biological Chemistry</i> , 2005, 280, 12523-12535.	1.6	35
8	Generation and characterization of a rabbit monoclonal antibody site-specific for tau O-GlcNAcylated at serine 400. <i>FEBS Letters</i> , 2013, 587, 3722-3728.	1.3	28
9	O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α -Synuclein Proteinopathies. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1296-1314.	1.7	24
10	Substrate determinants in the C99 juxtamembrane domains differentially affect β -secretase cleavage specificity and modulator pharmacology. <i>Journal of Neurochemistry</i> , 2013, 125, 610-619.	2.1	23
11	O11205: PHASE 1 STUDY IN HEALTHY VOLUNTEERS OF THE O-GLCNACASE INHIBITOR ASN120290 AS A NOVEL THERAPY FOR PROGRESSIVE SUPRANUCLEAR PALSY AND RELATED TAUOPATHIES. <i>Alzheimer's and Dementia</i> , 2018, 14, P251.	0.4	17
12	O30404: Pharmacological intervention with the novel α -GlcNAcase inhibitor ASN561 reduces pathological tau in transgenic mice. <i>Alzheimer's and Dementia</i> , 2015, 11, P227.	0.4	11
13	O1-10-01: PRECLINICAL PROFILES OF DRUG CANDIDATES PROMOTING O-LINKED GLYCOSYLATION OF TAU FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND TAUOPATHIES. , 2014, 10, P148-P149.		2